http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-941371-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c902faf6ae746c51fc8010672fc22894 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 1960-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1963-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-941371-A |
| titleOfInvention | Injectable pharmaceutical preparations comprising 6ยช -fluoroprednisolone and/or its 21-acetate |
| abstract | Injectable sterile aqueous suspensions comprise as essential active ingredient: 6a -fluoroprednisolone, which may be used in the form of the hydrate, and/or 6a -fluoroprednisolone-21-acetate and preferably contain about 2 to 60 mg./ml. of the active material. Optional ingredients include conventional preservatives, buffers, isotonic and suspending agents and, as complementary active ingredients there are mentioned antibiotics, e.g. neomycin, the penicillins, novobiocin, bacitracin, streptomycin, chloramphenicol, erythromycin, tetracycline, thiocymetin and polymyxin and vitamins, e.g. Vitamins A and B, riboflavin, pyridoxins, ascorbic acid and Vitamin B12. Specification 699,709 is referred to. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103301466-A |
| priorityDate | 1959-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.